

1 **NATIONAL INSTITUTE FOR HEALTH AND CARE**
2 **EXCELLENCE**

3 **Guideline scope**

4 **Diabetes (type 1 and type 2) in children and**
5 **young people: diagnosis and management**
6 **(update)**

7 This guideline will update the NICE guideline on diabetes (type 1 and type 2)
8 in children and young people: diagnosis and management (NG18).

9 The guideline will be developed using the methods and processes outlined in
10 [developing NICE guidelines: the manual](#).

11 This guideline will also be used to update the [NICE quality standard for](#)
12 [diabetes in children and young people](#).

13 **1 Why the update is needed**

14 New evidence that could affect recommendations was identified through the
15 surveillance process. Topic experts, including those who helped to develop
16 the existing guideline, advised NICE on whether areas should be updated or
17 new areas added. Full details are set out in the [surveillance review decision](#).

18 ***Why the guideline is needed***

19 Please see original guideline [scope](#).

20 **2 Who the guideline is for**

21 This guideline is for:

- 22 • healthcare professionals who care for children and young people with type
23 1 or type 2 diabetes
- 24 • commissioners and providers of NHS-funded healthcare services
- 25 • children and young people with type 1 or type 2 diabetes, and their families
26 and carers.

1 NICE guidelines cover health and care in England. Decisions on how they
2 apply in other UK countries are made by ministers in the [Welsh Government](#),
3 [Scottish Government](#) and [Northern Ireland Executive](#).

4 ***Equality considerations***

5 NICE carried out [an equality impact assessment](#) during development of the
6 original guideline. The assessment:

- 7 • lists equality issues identified, and how they have been addressed
- 8 • explains why any groups are excluded from the guideline.

9 **3 What the updated guideline will cover**

10 **3.1 Who is the focus?**

11 **Groups that will be covered**

- 12 • Children and young people (younger than 18 years) with type 1 diabetes.
- 13 • Children and young people (younger than 18 years) with type 2 diabetes.

14 Specific consideration will be given to:

- 15 • Children and young people from specific ethnic groups associated with a
16 high prevalence of diabetes.
- 17 • Children and young people with disabilities (including learning disabilities).
- 18 • Children and young people with comorbidities (medical or psychological
19 conditions).
- 20 • Children and young people with poor educational achievement.

21 **3.2 Settings**

22 **Settings that will be covered**

23 All settings where NHS-funded care is provided.

1 **3.3 *Activities, services or aspects of care***

2 **Key areas that will be covered in this update**

3 We will look at evidence in the areas below when developing this update. We
4 will consider making new recommendations or updating existing
5 recommendations in these areas only.

6 1 Type 1 diabetes.

7 – Monitoring for complications and associated conditions of
8 type 1 diabetes.

9 – Blood glucose monitoring.

10 2 Type 2 diabetes.

11 – Monitoring for complications and associated conditions of
12 type 2 diabetes.

13 3 Diabetic ketoacidosis.

14 – Fluid and insulin therapy.

15 **Proposed outline for the guideline**

16 The table below outlines all the areas that will be included in the guideline. It
17 sets out what NICE plans to do for each area in this update.

Area in the guideline	What NICE plans to do
1.1 Diagnosis	
Diagnosis	No evidence review: retain recommendations from existing guideline
1.2 Type 1 diabetes	
Education and information for children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Insulin therapy for children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Oral medicines for children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Dietary management for children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Exercise for children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Blood glucose and HbA1c targets and monitoring for children and young people with type 1 diabetes	Review evidence for blood glucose monitoring. No evidence review: retain recommendations from existing guideline for blood glucose targets and HbA1c targets and monitoring
Hyperglycaemia, blood ketone monitoring and intercurrent illness in children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Hypoglycaemia in children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Difficulties with maintaining optimal blood glucose control in children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Surgery for children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline

Area in the guideline	What NICE plans to do
Psychological and social issues in children and young people with type 1 diabetes	No evidence review: retain recommendations from existing guideline
Monitoring for complications and associated conditions of type 1 diabetes	Review evidence for managing periodontal disease. Retain existing recommendations 1.2.110-1.2.119
1.3 Type 2 diabetes	
Education and information for children and young people with type 2 diabetes	No evidence review: retain recommendations from existing guideline
Dietary management for children and young people with type 2 diabetes	No evidence review: retain recommendations from existing guideline
Metformin	No evidence review: retain recommendations from existing guideline
HbA1c targets and monitoring for children and young people with type 2 diabetes	No evidence review: retain recommendations from existing guideline
Surgery for children and young people with type 2 diabetes	No evidence review: retain recommendations from existing guideline
Psychological and social issues in children and young people with type 2 diabetes	No evidence review: retain recommendations from existing guideline
Monitoring for complications and associated conditions of type 2 diabetes	Review evidence for managing periodontal disease. Retain existing recommendations 1.3.43-1.3.57.
1.4 Diabetic ketoacidosis	
Recognition, referral and diagnosis	No evidence review: retain recommendations from existing guideline

Area in the guideline	What NICE plans to do
Initial management of diabetic ketoacidosis	No evidence review: retain recommendations from existing guideline
Fluid and insulin therapy	Review evidence and update existing recommendation as needed.
Monitoring during therapy	No evidence review: retain recommendations from existing guideline
Complications of diabetic ketoacidosis	No evidence review: retain recommendations from existing guideline
Avoiding future episodes of diabetic ketoacidosis	No evidence review: retain recommendations from existing guideline
1.5 Service provision	
Service provision	No evidence review: retain recommendations from existing guideline
Transition from paediatric to adult care	No evidence review: retain recommendations from existing guideline

1

2 Recommendations in areas that are being retained from the existing guideline
3 may be edited to ensure that they meet current editorial standards, and reflect
4 the current policy and practice context.

5 **Related NICE guidance**

6 ***Published***

- 7 • [Integrated sensor-augmented pump therapy systems for managing blood](#)
8 [glucose levels in type 1 diabetes \(the MiniMed Paradigm Veo system and](#)
9 [the Vibe and G4 PLATINUM CGM system\)](#) (2016) NICE Diagnostics
10 guidance 21
- 11 • [Type 2 diabetes in adults: management](#) (2015) NICE guideline NG28

- 1 • [Type 1 diabetes in adults: diagnosis and management](#) (2015) NICE
2 guideline NG17
- 3 • [Coeliac disease recognition, assessment and management](#) (2015) NICE
4 guideline NG20
- 5 • [Diabetic foot problems: prevention and management](#) (2015) NICE guideline
6 NG19
- 7 • [Type 2 diabetes: prevention in people at high risk](#) (2012) NICE guideline
8 PH38
- 9 • [Generalised anxiety disorder and panic disorder in adults: management](#)
10 (2011) NICE guideline CG113
- 11 • [Preventing type 2 diabetes: population and community-level interventions](#)
12 (2011) NICE guideline PH35
- 13 • [Physical activity for children and young people](#) (2009) NICE guideline PH17
- 14 • [Continuous subcutaneous insulin infusion for the treatment of diabetes](#)
15 [mellitus](#) (2008) NICE technology appraisal TA151
- 16 • [Obesity prevention](#) (2006) NICE guideline CG43
- 17 • [Dental checks: intervals between oral health reviews](#) (2004) NICE clinical
18 guideline CG19

19 ***In development***

- 20 • [Babies, children and young people's experience of healthcare](#). NICE
21 guideline. Publication expected April 2021

22 **NICE guidance about the experience of people using NHS services**

23 NICE has produced the following guidance on the experience of people using
24 the NHS. This guideline will not include additional recommendations on these
25 topics unless there are specific issues related to diabetes in children:

- 26 • [Medicines optimisation](#) (2015) NICE guideline NG5
- 27 • [Medicines adherence](#) (2009) NICE guideline CG76

28 **3.4 Economic aspects**

29 We will take economic aspects into account when making recommendations.

30 We will develop an economic plan that states for each review question (or key

1 area in the scope) whether economic considerations are relevant, and if so
2 whether this is an area that should be prioritised for economic modelling and
3 analysis. We will review the economic evidence and carry out economic
4 analyses, using an NHS, public sector and other perspectives, as appropriate.

5 ***Key issues and draft questions***

6 While writing the scope for this updated guideline, we have identified the
7 following key issues and draft questions related to them:

8 1 Type 1 and type 2 diabetes: monitoring for complications and associated
9 conditions

10 1.1 In children and young people with type 1 or type 2 diabetes, what is
11 the effectiveness of periodontal treatment to improve diabetic control?

12 2 Blood glucose monitoring for children and young people with type 1
13 diabetes

14 2.1 In children and young people with type 1 diabetes, what is the most
15 effective method of blood glucose monitoring to improve diabetic control:

- 16 – continuous glucose monitoring
- 17 – flash glucose monitoring
- 18 – intermittent capillary blood glucose monitoring?

19 3 Diabetic ketoacidosis: fluid and insulin therapy

20 3.1 In children and young people with diabetic ketoacidosis:

- 21 – what is the appropriate route of fluid administration for rehydration?
- 22 – what fluids (including additives) should be used for rehydration?
- 23 – at what rate, including volume of fluid should children and young
24 people be rehydrated?

25

26 The key issues and draft questions will be used to develop more detailed
27 review questions, which guide the systematic review of the literature.

28 **3.5 *Main outcomes***

29 The main outcomes that may be considered when searching for and
30 assessing the evidence are:

- 1 • Glycaemic control.
- 2 • Any adverse effects of interventions used to manage type 1 or type 2
- 3 diabetes.
- 4 • Health-related quality of life (validated questionnaire), for example,
- 5 diabetes-specific health-related quality of life.
- 6 • Complications of diabetes.
- 7 • Mortality.
- 8 • Psychological outcomes.
- 9 • Patient satisfaction.

10 **4 NICE quality standards and NICE Pathways**

11 **4.1 NICE quality standards**

12 **NICE quality standards that may need to be revised or updated when** 13 **this guideline is published**

- 14 • [Diabetes in children and young people](#) (2016) NICE quality standard 125

15 **4.2 NICE Pathways**

16 When this guideline is published, we will update the existing NICE Pathway on
17 [diabetes in children and young people](#). NICE Pathways bring together
18 everything NICE has said on a topic in an interactive flowchart.

19 **5 Further information**

This is the final scope.

The guideline is expected to be published: to be confirmed.

You can follow progress of the [guideline](#).

Our website has information about how [NICE guidelines](#) are developed.

20

21 © NICE 2020. All rights reserved. Subject to [Notice of rights](#).